DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Simeprevir
Simeprevir
Drug Repurposing for Identification of Potential Inhibitors Against SARS-Cov-2 Spike Receptor-Binding Domain: an in Silico Approach
OLYSIO (Simeprevir) Capsules, for Oral Use Ribavirin May Cause Birth Defects and Fetal Death and Animal Studies Initial U.S
Pharmaceutical Targeting the Envelope Protein of SARS-Cov-2: the Screening for Inhibitors in Approved Drugs
Informatorium of COVID-19 Drugs in Indonesia" Has Been Compiled and Can Be Published Amidst the COVID-19 Outbreak in Indonesia
Estonian Statistics on Medicines 2016 1/41
Antiviral Effects of Simeprevir on Multiple Viruses
Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018
Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize With
Simeprevir Potently Suppresses SARS-Cov-2 Replication and Synergizes with Remdesivir
Simeprevir PK Fact Sheet Reviewed March 2016 Page 1 of 2 for Personal Use Only
Curing Chronic Hepatitis C: a Cost Comparison of the Combination Simeprevir Plus Sofosbuvir Vs
Olysio® (Simeprevir), Sovaldi® (Sofosbuvir), & Ribavirin Treatment Agreement
Repurposing Simeprevir, Calpain Inhibitor IV and a Cathepsin F Inhibitor Against SARS-Cov-2: a Study Using in Silico Pharmacophore Modeling and Docking Methods
Simeprevir (Olysio)
Influenza a Virus Hemagglutinin Mutations Associated with Use of Neuraminidase Inhibitors Correlate with Decreased Inhibition by Anti-Influenza Antibodies Natalia A
Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
Interferon-Based Simeprevir Therapy for Pediatric Patients with Chronic Hepatitis C Viral Infection
Hepatitis C Treatment Factsheet Simeprevir (Olysio)
Top View
Resistance-Associated Polymorphisms in Dutch Hepatitis C Genotype 1A Patients with and Without HIV Infection
The Cost Effectiveness of a Novel High Priced Combination
Simeprevir (Olysio ™) UTILIZATION MANAGEMENT CRITERIA
Olysio ®) SMC No
Simeprevir with Pegylated Interferon Alfa 2A Plus Ribavirin For
Olysio) Reference Number: CP.PHAR.280 Effective Date: 09.16 Last Review Date: 02.20 Line of Business: Medicaid Revision Log
Anatomisch-Therapeutisch- Chemische Klassifikation Mit Tagesdosen Für
Efficacy and Safety of Simeprevir in Combination with Sofosbuvir, Once-Daily, for Genotype 1 Chronic Hepatitis C
Simeprevir, Potential Candidate to Repurpose for Coronavirus Infection
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Simeprevir Drug Monograph
Olysio (Simeprevir)
Olysio® (Simeprevir) & Sovaldi® (Sofosbuvir) Treatment Agreement
Should Protease Inhibitors Be Used for COVID-19?
Target-Centered Drug Repurposing Predictions of Human Angiotensin
Olysio, INN-Simeprevir
Retreatment of Genotype 1 Hepatitis C Virus with Sofosbuvir, Simeprevir, and Ribavirin Following Treatment Failure with an NS5A
OLYSIO (Simeprevir) Capsules, for Oral Use ------DOSAGE FORMS and STRENGTHS------ Initial U.S
Anti-Infectives for Systemic Use Prescribed in a Spanish Hospital Between 2009‑2013
Simeprevir with Peginterferon Α-2A/Ribavirin for Chronic Hepatitis C
Combination Therapy with Simeprevir and TMC647055/Low Dose Ritonavir: Dose Anticipation Using PBPK Modeling and Dose Optimization in Healthy Subjects
Identification of Novel Compounds Against Three Targets of SARS Cov-2 Coronavirus by Combined Virtual Screening and Supervised Machine Learning
Attachment A)
Repositioning of 8565 Existing Drugs for COVID-19
Learningpharmacology 2018.Pdf
Selected Properties of Simeprevir Other Names Galexos®, TMC435
Simeprevir Suppresses SARS-Cov-2 Replication and Synergizes with Remdesivir
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment
ESAC-Net Reporting Protocol 2018.Docx Introduction
Drug Class Review Monograph – GPI Class 12 – Antivirals Review Time Frame: 02/2016 – 04/2017 Previous Class Review: 05/2016
1 Who Model List of Essential Medicines Application
Potentially Highly Potent Drugs for 2019-Ncov